Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Other Accumulated Expenses (2020 - 2026)

Inhibikase Therapeutics (IKT) has 7 years of Other Accumulated Expenses data on record, last reported at $109350.0 in Q1 2026.

  • On a quarterly basis, Other Accumulated Expenses fell 14.37% to $109350.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $109350.0, a 14.37% decrease, with the full-year FY2025 number at $212927.0, up 162.87% from a year prior.
  • Other Accumulated Expenses reached $109350.0 in Q1 2026 per IKT's latest filing, down from $212927.0 in the prior quarter.
  • Over the last five years, Other Accumulated Expenses for IKT hit a ceiling of $212927.0 in Q4 2025 and a floor of $100.0 in Q1 2023.
  • A 5-year average of $55688.5 and a median of $25561.0 in 2024 define the central range for Other Accumulated Expenses.
  • Peak YoY movement for Other Accumulated Expenses: tumbled 99.69% in 2023, then skyrocketed 25461.0% in 2024.
  • Tracing IKT's Other Accumulated Expenses over 5 years: stood at $9920.0 in 2022, then skyrocketed by 936.46% to $102817.0 in 2023, then decreased by 21.22% to $81000.0 in 2024, then skyrocketed by 162.87% to $212927.0 in 2025, then crashed by 48.64% to $109350.0 in 2026.
  • Business Quant data shows Other Accumulated Expenses for IKT at $109350.0 in Q1 2026, $212927.0 in Q4 2025, and $116166.0 in Q3 2025.